Granules India Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Granules India ha aumentado sus beneficios a una tasa media anual de 10.4%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 14.8% anual. Los ingresos han ido creciendo a una tasa media de 15.5% al año. La rentabilidad financiera de Granules India es de 13.3%, y sus márgenes netos son de 8.7%.

Información clave

10.4%

Tasa de crecimiento de los beneficios

11.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	17.5%
Tasa de crecimiento de los ingresos	15.5%
Rentabilidad financiera	13.3%
Margen neto	8.7%
Próxima actualización de resultados	15 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Investors Holding Back On Granules India Limited (NSE:GRANULES)

Apr 08

Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next

Jan 26

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Dec 21

Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock

Aug 18

Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25

Aug 03

Is Granules India (NSE:GRANULES) Using Too Much Debt?

Jun 11

Why Granules India Limited (NSE:GRANULES) Is A Dividend Rockstar

May 02

Does This Valuation Of Granules India Limited (NSE:GRANULES) Imply Investors Are Overpaying?

Mar 26

What Kind Of Investors Own Most Of Granules India Limited (NSE:GRANULES)?

Mar 14

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Mar 01

Granules India Limited (NSE:GRANULES) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Feb 16

Why You Might Be Interested In Granules India Limited (NSE:GRANULES) For Its Upcoming Dividend

Feb 03

Analysts Have Made A Financial Statement On Granules India Limited's (NSE:GRANULES) Third-Quarter Report

Jan 30

Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching

Jan 20

Have Insiders Sold Granules India Limited (NSE:GRANULES) Shares Recently?

Jan 07

Announcing: Granules India (NSE:GRANULES) Stock Increased An Energizing 198% In The Last Year

Dec 28

Granules India Limited's (NSE:GRANULES) Attractive Combination: Does It Earn A Place In Your Dividend Portfolio?

Dec 15

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Granules India. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NSEI:GRANULES Ingresos, gastos y beneficios (INR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	45,261	3,953	5,877	0
30 Sep 23	45,166	3,939	5,499	0
30 Jun 23	44,779	4,369	5,187	0
31 Mar 23	45,119	5,166	4,872	0
31 Dec 22	43,464	5,080	4,781	0
30 Sep 22	41,970	4,845	4,643	0
30 Jun 22	39,346	4,201	4,391	0
31 Mar 22	37,649	4,128	4,123	0
31 Dec 21	35,343	4,293	4,113	0
30 Sep 21	33,820	4,753	4,069	0
30 Jun 21	33,518	5,582	4,189	0
31 Mar 21	32,375	5,495	4,248	0
31 Dec 20	30,381	5,142	3,412	0
30 Sep 20	28,976	4,314	3,228	0
30 Jun 20	27,390	3,636	2,857	0
31 Mar 20	25,986	3,354	3,217	0
31 Dec 19	26,121	3,071	2,537	0
30 Sep 19	25,399	3,034	2,425	0
30 Jun 19	24,212	2,679	2,166	0
31 Mar 19	22,792	2,364	2,269	0
31 Dec 18	21,697	1,928	2,158	0
30 Sep 18	19,487	1,675	2,037	0
30 Jun 18	17,603	1,476	1,764	0
31 Mar 18	16,846	1,326	1,801	0
31 Dec 17	15,361	1,578	1,692	0
30 Sep 17	14,785	1,619	1,638	0
30 Jun 17	14,456	1,624	1,453	0
31 Mar 17	14,106	1,645	1,504	0
31 Dec 16	14,971	1,473	1,614	85
30 Sep 16	14,626	1,374	1,479	63
30 Jun 16	14,524	1,289	1,423	28
31 Mar 16	13,572	1,230	1,283	0
31 Dec 15	14,147	1,077	2,377	187
30 Sep 15	13,895	1,041	2,366	160
30 Jun 15	13,307	952	2,317	134
31 Mar 15	12,937	909	1,155	0
31 Dec 14	12,573	921	2,261	51
30 Sep 14	12,217	904	2,188	57
30 Jun 14	11,786	834	1,472	64
31 Mar 14	10,973	752	2,051	94
31 Dec 13	9,837	640	1,656	49
30 Sep 13	8,948	480	1,569	51
30 Jun 13	8,034	410	1,105	48

Ingresos de calidad: GRANULES tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(8.7%) de GRANULES son inferiores a los del año pasado (11.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de GRANULES han crecido un 10.4% al año en los últimos 5 años.

Acelerando crecimiento: GRANULES ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: GRANULES tuvo un crecimiento negativo de los beneficios (-22.2%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (23.8%).

Granules India Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Granules India Limited to Report Q4, 2024 Results on May 15, 2024

Third quarter 2024 earnings released: EPS: ₹5.18 (vs ₹5.11 in 3Q 2023)

Granules India Limited to Report Q3, 2024 Results on Jan 23, 2024

Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹5.85 in 2Q 2023)

Granules India Limited to Report Q2, 2024 Results on Nov 09, 2023

Granules India Limited to Report Q1, 2024 Results on Aug 09, 2023

Recent updates

Granules India Limited to Report Q4, 2024 Results on May 15, 2024

High number of new directors

Investors Holding Back On Granules India Limited (NSE:GRANULES)

Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer

Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing

Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings released: EPS: ₹5.18 (vs ₹5.11 in 3Q 2023)

Granules India Limited to Report Q3, 2024 Results on Jan 23, 2024

Many Still Looking Away From Granules India Limited (NSE:GRANULES)

Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets

Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet

Price target increased by 8.1% to ₹375

Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹5.85 in 2Q 2023)

Granules India Limited to Report Q2, 2024 Results on Nov 09, 2023

A Look At The Fair Value Of Granules India Limited (NSE:GRANULES)

Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules

Granules India Limited Approves Final Dividend for the Fy 2022-23

Granules India Limited Receives US FDA Approval for the ANDA Files for Metoprolol Succinate ER Tablets Registered Office

Granules India Limited to Report Q1, 2024 Results on Aug 09, 2023

Upcoming dividend of ₹1.50 per share at 0.5% yield

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Granules India Limited Announces Approval for the Store Brand OTC Equivalent of Advil®? Dual Action Tablets Registered Office

Granules India Limited Receives ANDA Approval for Venlafaxine ER Capsules

Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?

Granules India Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Should You Be Adding Granules India (NSE:GRANULES) To Your Watchlist Today?

Third quarter 2023 earnings: EPS misses analyst expectations

Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet

Granules India Limited to Report Q3, 2023 Results on Jan 24, 2023

Granules India Limited Announces Resignation of Sandip Neogi as Chief Financial Officer (Cfo)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Granules India Limited to Report Q2, 2023 Results on Oct 20, 2022

Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?

Granules India Limited Receives Approval for Abbreviated New Drug Application from US Food & Drug Administration

Estimating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)

Price target increased to ₹338

Granules India Limited (BSE:532482) announces an Equity Buyback for 6,250,000 shares, representing 2.52% for INR 2,500 million.

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Granules India Limited to Report Q1, 2023 Results on Aug 09, 2022

Granules India Limited Approves Final Dividend for the Financial Year 2021-22

Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.75

Upcoming dividend of ₹0.75 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Is Granules India (NSE:GRANULES) A Risky Investment?

Now 21% undervalued after recent price drop

Price target decreased to ₹319

Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.75

Granules India Limited, Annual General Meeting, Jul 27, 2022

Price target decreased to ₹330

Granules India Recommends Final Dividend for the Financial Year 2021-22

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Fair Value Of Granules India Limited (NSE:GRANULES)

Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.25

Granules India Limited Declares Third Interim Dividend for the Financial Year 2021-22

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Calculating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)

Now 21% undervalued after recent price drop

Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Insufficient new directors

Second quarter 2022 earnings released: EPS ₹3.26 (vs ₹6.60 in 2Q 2021)

Upcoming dividend of ₹0.25 per share

Price target decreased to ₹388

Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock

Insider recently sold ₹1.2m worth of stock

Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25

Upcoming dividend of ₹0.25 per share

Desglose de ingresos y gastos
Beta